Program
Gemfibrozil
Also written as “PLX-200”, “Gemfibrozil Tablets” and “gemfibrozil”.
Its studies are mostly in Neuronal Ceroid-Lipofuscinoses · Parkinson Disease · Lysosomal Storage Diseases · Anemia · Diabetes Mellitus, Type 2, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Polaryx Therapeutics | 21 open or running | phase 3since Nov 4, 2020 | Nov 4, 2020 | Dec 31, 2028phase 2 · NCT07740512 |
| Blu Caribe | 10 open or running | phase 1since Nov 26, 2008 | Nov 26, 2008 | none ahead |
| Eli Lilly | 10 open or running | phase 1since Nov 26, 2012 | Nov 26, 2012 | none ahead |
| Elixir Pharmaceuticals | 10 open or running | phase 1since Dec 3, 2007 | Dec 3, 2007 | none ahead |
| Forest Hills Lab | 10 open or running | phase 2since Jun 15, 2023 | Jun 15, 2023 | none ahead |
| GlaxoSmithKline | 10 open or running | phase 1since Jun 16, 2011 | Jun 16, 2011 | none ahead |
| Johnson & Johnson | 10 open or running | phase 1since May 11, 2016 | May 11, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 3, 2007First study: phase 1 study in Diabetes Mellitus, Type 2New to Elixir PharmaceuticalsElixir Pharmaceuticals · NCT00566865 · 14 enrolled
- Nov 26, 2008Blu Caribe's first study: phase 1 study in BioavailabilityNew to Blu CaribeBlu Caribe · NCT00800475 · 40 enrolled
- Jun 16, 2011GlaxoSmithKline's first study: phase 1 study in AnemiaNew to GlaxoSmithKlineGlaxoSmithKline · NCT01376232 · 23 enrolled · India
- Nov 26, 2012Eli Lilly's first study: phase 1 study in Healthy VolunteersNew to Eli LillyEli Lilly · NCT01736254 · 24 enrolled · United States
- May 11, 2016Johnson & Johnson's first study: phase 1 study in Healthy SubjectsNew to Johnson & JohnsonJohnson & Johnson · NCT02770222 · 40 enrolled
- Nov 4, 2020Polaryx Therapeutics's first study: phase 3 study in Neuronal Ceroid-LipofuscinosesNew to Polaryx TherapeuticsPolaryx Therapeutics · NCT04637282
- Jun 15, 2023Forest Hills Lab's first study: phase 2 study in Parkinson DiseaseNew to Forest Hills LabForest Hills Lab · NCT05931484
- Jul 17, 2026Phase 2 study in Lysosomal Storage DiseasesPolaryx Therapeutics · NCT07740512 · 24 planned
Ahead
- Dec 31, 2028Primary completion: phase 2 study in Lysosomal Storage DiseasesPolaryx Therapeutics · NCT07740512
TargetBeta
“Peroxisome proliferator-activated receptor alpha agonist”ChEMBL 37, by rule
Other programs on PPARA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| saroglitazarrule | Zydus Lifesciences | phase 4 | 19 |
| pemafibraterule | Kowa | phase 4 | 17 |
| elifibranorrule | Genfit | phase 3 | 24 |
| seladelparrule | Gilead Sciences | phase 3 | 14 |
| chiglitazarrule | Chipscreen Biosciences | phase 3 | 9 |
| lanifibranor | inventiva-pharma | phase 3 | 6 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07740512Lysosomal Storage Diseases | 2 | Not yet recruiting | Polaryx Therapeutics | Dec 31, 2028 | 24 |
| NCT05931484Parkinson Disease | 2 | Withdrawn | Forest Hills Lab | Nov 1, 2028 | 0 |
| NCT04637282Neuronal Ceroid-Lipofuscinoses | 3 | Withdrawn | Polaryx Therapeutics | Dec 31, 2026 | 0 |
| NCT02770222Healthy Subjects | 1 | Completed | Johnson & Johnson | Jul 2016 | 40 |
| NCT01736254Healthy Volunteers · United States | 1 | Completed | Eli Lilly | Feb 2013 | 24 |
| NCT01376232Anemia · India | 1 | Completed | GlaxoSmithKline | Dec 20, 2010 | 23 |
| NCT00800475Bioavailability | 1 | Completed | Blu Caribe | Jul 2005 | 40 |
| NCT00566865Diabetes Mellitus, Type 2 | 1 | Completed | Elixir Pharmaceuticals | Dec 2007 | 14 |
How it is read
Names in the registry
- “Gemfibrozil”, 4 entries
- “PLX-200”, 2 entries
- “Gemfibrozil Tablets”, 1 entry
- “gemfibrozil”, 1 entry
Conditions, from the studies’ own filings
- Neuronal Ceroid-Lipofuscinoses, 1 study
- Parkinson Disease, 1 study
- Lysosomal Storage Diseases, 1 study
- Anemia, 1 study
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.